Company Overview

Defence Therapeutics Inc. is a Canadian biotechnology company focused on the development of novel immunotherapy and antibody‑drug conjugate (ADC) technologies for the treatment of cancer and infectious diseases. The company operates within the biotechnology and life sciences industries, with its activities centered on research and development rather than commercial-stage product sales. Its core value proposition is the proprietary Accum™ technology platform, which is designed to enhance the intracellular delivery and efficacy of therapeutic agents.

The company’s primary business lines include oncology immunotherapies, ADCs, and vaccine enhancement technologies, all of which are in preclinical or early clinical development stages based on publicly available disclosures. Defence Therapeutics primarily serves pharmaceutical research partners, academic collaborators, and, in the long term, oncology and infectious disease patient populations. The company traces its origins to earlier-stage Canadian biotech ventures and has evolved into a focused R&D organization following corporate restructuring and rebranding; detailed historical timelines beyond this are limited, and certain early corporate lineage details remain inconclusive based on available public sources.

Business Operations

Defence Therapeutics operates as a single integrated biotechnology enterprise with its activities organized around the Accum™ technology platform, which underpins multiple therapeutic programs. Revenue generation to date has been limited and primarily associated with research funding, government grants, and strategic collaborations rather than product commercialization. The company does not currently report material recurring commercial revenue, consistent with its development-stage profile.

Operations are primarily research-driven, with laboratory and scientific capabilities supporting oncology programs such as ACCUM‑based ADCs and immune‑oncology candidates. The company maintains intellectual property related to intracellular drug delivery and works with external research institutions and contract research organizations. Public disclosures indicate no large-scale manufacturing assets, and information on formal joint ventures or revenue-generating subsidiaries is limited; where referenced, such structures remain immaterial to consolidated operations.

Strategic Position & Investments

Strategically, Defence Therapeutics positions itself as a platform innovator seeking to improve the therapeutic index of existing and next-generation biologics. Growth initiatives focus on advancing lead oncology assets through preclinical validation, securing intellectual property protections, and pursuing strategic partnerships with larger pharmaceutical companies. The company has publicly highlighted the potential application of Accum™ across multiple therapeutic modalities, including vaccines and ADCs.

Investment activity has primarily centered on internal R&D and patent portfolio expansion rather than major acquisitions. No transformative acquisitions or controlling investments in external operating companies have been conclusively verified through public filings. Engagement in emerging sectors such as precision oncology and immune modulation is evident, though timelines for clinical-stage advancement remain subject to regulatory and scientific uncertainty.

Geographic Footprint

Defence Therapeutics is headquartered in Canada, with its core research and corporate activities based there. The company’s operational footprint is relatively компакт, reflecting its development-stage status, and does not include broad commercial infrastructure across multiple continents.

Despite this, the company maintains an international orientation through scientific collaborations, intellectual property filings, and capital market participation, including trading in North America via U.S. over‑the‑counter markets. References to activities or partnerships in the United States and Europe are present in corporate communications, but the scale and permanence of these international operations cannot be fully substantiated from publicly available data.

Leadership & Governance

Defence Therapeutics is led by an executive team with backgrounds in biotechnology commercialization, immunology, and corporate finance. Leadership emphasizes platform scalability, scientific rigor, and long-term value creation through intellectual property and strategic partnerships. Governance practices are aligned with publicly listed Canadian life sciences companies, though the company remains founder‑influenced in strategic direction.

Key executives include:

• Sébastien Plouffe – Chief Executive Officer
• Dr. Moutih Rafei – Chief Scientific Officer
• André Larocque – Chief Financial Officer

Information regarding additional executive officers and board committee structures is limited, and some governance details are inconclusive based on available public sources.